These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34328656)

  • 1. High level of phosphatidylcholines/lysophosphatidylcholine ratio in urine is associated with prostate cancer.
    Li X; Nakayama K; Goto T; Kimura H; Akamatsu S; Hayashi Y; Fujita K; Kobayashi T; Shimizu K; Nonomura N; Ogawa O; Inoue T
    Cancer Sci; 2021 Oct; 112(10):4292-4302. PubMed ID: 34328656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of the extraction and analysis of urinary phospholipids and lysophospholipids using MALDI-TOF/MS.
    Li X; Nakayama K; Goto T; Akamatsu S; Shimizu K; Ogawa O; Inoue T
    Chem Phys Lipids; 2019 Sep; 223():104787. PubMed ID: 31255592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parameters affecting the accuracy of the MALDI-TOF MS determination of the phosphatidylcholine/lysophosphatidylcholine (PC/LPC) ratio as potential marker of spermatozoa quality.
    Bresler K; Pyttel S; Paasch U; Schiller J
    Chem Phys Lipids; 2011 Oct; 164(7):696-702. PubMed ID: 21827741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer.
    Goto T; Terada N; Inoue T; Kobayashi T; Nakayama K; Okada Y; Yoshikawa T; Miyazaki Y; Uegaki M; Utsunomiya N; Makino Y; Sumiyoshi S; Yamasaki T; Kamba T; Ogawa O
    Prostate; 2015 Dec; 75(16):1821-30. PubMed ID: 26332786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.
    Nakayama K; Inoue T; Sekiya S; Terada N; Miyazaki Y; Goto T; Kajihara S; Kawabata S; Iwamoto S; Ikawa K; Oosaga J; Tsuji H; Tanaka K; Ogawa O
    PLoS One; 2014; 9(9):e107234. PubMed ID: 25233230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary prostate specific antigen: is the clinical use likely?
    Pejcic T; Hadzi-Djokic J; Acimovic M; Topuzovic C; Milkovic B; Janjic A
    Acta Chir Iugosl; 2005; 52(4):69-74. PubMed ID: 16673599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approach in determination of urinary diagnostic markers for prostate cancer by MALDI-TOF/MS.
    Buszewska-Forajta M; Pomastowski P; Monedeiro F; Król-Górniak A; Adamczyk P; Markuszewski MJ; Buszewski B
    Talanta; 2022 Jan; 236():122843. PubMed ID: 34635233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
    Rehman I; Azzouzi AR; Catto JW; Allen S; Cross SS; Feeley K; Meuth M; Hamdy FC
    Urology; 2004 Dec; 64(6):1238-43. PubMed ID: 15596215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
    Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
    Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualization of phosphatidylcholine, lysophosphatidylcholine and sphingomyelin in mouse tongue body by matrix-assisted laser desorption/ionization imaging mass spectrometry.
    Enomoto H; Sugiura Y; Setou M; Zaima N
    Anal Bioanal Chem; 2011 Jun; 400(7):1913-21. PubMed ID: 21472363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling.
    Cheng HL; Huang HJ; Ou BY; Chow NH; Chen YW; Tzai TS; Wu CJ; Chen SH
    Proteomics Clin Appl; 2011 Apr; 5(3-4):121-32. PubMed ID: 21322116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.
    Yun SJ; Yan C; Jeong P; Kang HW; Kim YH; Kim EA; Lee OJ; Kim WT; Moon SK; Kim IY; Choi YH; Kim WJ
    Ann Surg Oncol; 2015 Jul; 22(7):2439-45. PubMed ID: 25348783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine.
    M'Koma AE; Blum DL; Norris JL; Koyama T; Billheimer D; Motley S; Ghiassi M; Ferdowsi N; Bhowmick I; Chang SS; Fowke JH; Caprioli RM; Bhowmick NA
    Biochem Biophys Res Commun; 2007 Feb; 353(3):829-34. PubMed ID: 17194448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of individual phospholipids in lipid mixtures by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: phosphatidylcholine prevents the detection of further species.
    Petkovic M; Schiller J; Müller M; Benard S; Reichl S; Arnold K; Arnhold J
    Anal Biochem; 2001 Feb; 289(2):202-16. PubMed ID: 11161314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for monitoring the digestion of phosphatidylcholine by pancreatic phospholipase A(2).
    Petković M; Müller J; Müller M; Schiller J; Arnold K; Arnhold J
    Anal Biochem; 2002 Sep; 308(1):61-70. PubMed ID: 12234464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MALDI MS profiling of post-DRE urine samples highlights the potential of β-microseminoprotein as a marker for prostatic diseases.
    Flatley B; Wilmott KG; Malone P; Cramer R
    Prostate; 2014 Jan; 74(1):103-11. PubMed ID: 24115268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
    Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
    J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous Analysis of Multiple Cancer Biomarkers Using MALDI-TOF Mass Spectrometry Based on a Parylene-Matrix Chip.
    Park JM; Kim MJ; Noh JY; Yun TG; Kang MJ; Lee SG; Yoo BC; Pyun JC
    J Am Soc Mass Spectrom; 2020 Apr; 31(4):917-926. PubMed ID: 32154716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.